<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039216</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/21/0163</org_study_id>
    <nct_id>NCT05039216</nct_id>
  </id_info>
  <brief_title>Biobank for Inflammatory Chronic Diseases and Osteoporosis</brief_title>
  <acronym>BIOTOUL</acronym>
  <official_title>Biobank for Inflammatory Chronic Diseases and Osteoporosis of TOULouse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to constitute a biobank for patients followed in the Rheumatology&#xD;
      center of Toulouse University Hospital for a chronic inflammatory rheumatism including&#xD;
      rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic&#xD;
      bone disease including osteoporosis in order to identify biomarkers associated with&#xD;
      therapeutic response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologic ant targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs and tsDMARDs)&#xD;
      have greatly improved the prognosis of chronic inflammatory diseases. To date, many bDMARDs&#xD;
      and tsDMARDs targeting different immunologic mechanisms are available to treat RA, SpA or&#xD;
      PsA. However, the choice of the treatment and its mechanism of action is based on physician&#xD;
      decision and experience. Indeed, predictive clinical and biological factors associated with&#xD;
      therapeutic response that could help the physician to make his/her choice are lacking. The&#xD;
      aim of BIO-TOUL is to collect and store biologic samples in patients with RA, SpA or PsA who&#xD;
      begin a new bDMARD or tsDMARD. This biobank will permit to study several biomarkers and&#xD;
      assess the association between such markers and response to therapy.&#xD;
&#xD;
      Furthermore, osteoporosis is a chronic disease leading to fractures and disability. Several&#xD;
      ant-osteoporotic drugs are now available and biomarker(s) that would help the physician to&#xD;
      choose the best therapeutic sequence are lacking. BIO-TOUL will also include patients with&#xD;
      osteoporosis to identify biomarkers associated with severity and response to&#xD;
      anti-osteoporotic treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EULAR response after 3 months</measure>
    <time_frame>after 3 months</time_frame>
    <description>EULAR response after 3 months</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>patients initiating a biotherapy or a target treatment</arm_group_label>
    <description>Blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with chronic inflammatory rheumatism, weakening osteopathy or mechanical pathology</arm_group_label>
    <description>Blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>4 tubes of 7 mL will be sampled</description>
    <arm_group_label>patients initiating a biotherapy or a target treatment</arm_group_label>
    <arm_group_label>patients with chronic inflammatory rheumatism, weakening osteopathy or mechanical pathology</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        monocentric observational longitudinal study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic inflammatory rheumatism including RA, SpA or PsA or patients with primary or&#xD;
             secondary osteoporosis&#xD;
&#xD;
          -  Aged &gt; 18 ans&#xD;
&#xD;
          -  With National Health Assurance&#xD;
&#xD;
          -  Able to consent to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Not able to give a consent&#xD;
&#xD;
          -  Severe anemia (Hb&lt;10g/L)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adeline RUYSSEN-WITRAND, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adeline RUYSSEN-WITRAND, MD</last_name>
    <phone>561775626</phone>
    <phone_ext>0033</phone_ext>
    <email>ruyssen-witrand.a@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine THUILLEZ</last_name>
    <phone>561776966</phone>
    <phone_ext>0033</phone_ext>
    <email>thuillez.d@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Purpan University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline RUYSSEN-WITRAND, PU-PH</last_name>
      <phone>561775626</phone>
      <phone_ext>0033</phone_ext>
      <email>ruyssen-witrand.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

